What Is the Starting Dose of Compounded Semaglutide?

Semaglutide for weight management is not started at the dose that produces the published results. It is started well below it and stepped up over months, and the schedule exists because the drug's side effects are dose-related while its kinetics are slow — the elimination half-life is approximately one week^[1]. A compounded vial inherits that schedule from the brand evidence without inheriting approved labeling of its own, and it adds a step the pen never asked of you: converting a milligram dose into a syringe reading^[3].

The shape of the schedule

The approved weight-management dose ladder for semaglutide runs 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg once weekly, with roughly four weeks at each step. The first rung is an initiation dose: it is not intended as a treatment dose, and it exists so the gastrointestinal tract can adapt before therapeutic exposure arrives. Reaching the top of the ladder therefore takes months rather than weeks, by design.

The four-week spacing follows from the pharmacology rather than convention. With a half-life of about a week^[1], blood levels continue rising for several doses after each increase before they plateau — earlier pharmacokinetic work attributed that long half-life to albumin binding and resistance to enzymatic degradation^[2]. Assessing tolerability two weeks after a step means assessing an exposure that has not finished climbing.

What is different about a compounded vial

• The schedule is inherited, not approved. Compounded semaglutide carries no FDA-approved dosing labeling. A provider using the familiar ladder is extrapolating from the brand evidence — defensible, but worth naming as an extrapolation rather than a label instruction.
• Your dose is in milligrams; your syringe is in units. The number of units that delivers 0.25 mg depends entirely on the vial's concentration, and it changes when the vial does. Our units conversion article works through the arithmetic in both directions.
• Non-standard ladders exist in this market. Some compounded programs use doses that do not appear on the approved ladder at all. That is not automatically unreasonable, but the published efficacy figures describe the approved doses, so those results do not transfer to an unfamiliar schedule.
• The dangerous error at initiation is measurement, not prescription. A poison control case series recorded patients who had the right prescription and measured it on the wrong scale, taking multiples of the intended dose^[3].
• Batch-to-batch consistency is not a given. Work on follow-on and compounded GLP-1 receptor agonists has examined impurity profiles and potential immunogenicity^[4], so the same nominal product is not guaranteed to be identical each time.

Escalating well

The two failure modes are opposite and equally common. Rushing the ladder concentrates the dose-related gastrointestinal effects into the period when tolerance is lowest, which is a reliable way to stop treatment early — and a medication discontinued at week six delivers nothing. Stalling permanently on the initiation dose completes the adaptation period without reaching a dose the efficacy evidence describes. Both can be reasonable in an individual case; neither should happen by drift.

Holding a dose longer than four weeks is a normal part of the schedule rather than a failure of it, and dose reduction for tolerability is an anticipated move. What is not advisable is adjusting either one yourself by changing how many units you draw, because that decouples what you are taking from what anyone has prescribed or recorded.